Blueprint Medicines stock was soaring Monday after French drugmaker Sanofi said it had agreed to buy the biotech company for ...

Blueprint Medicines came under pressure from Wall Street on Monday after at least six brokerages downgraded the stock ...

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a ...

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for up to $9.5 billion, sending shares of ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an ...

We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other top ...

Also Read: Blood Cancer-Focused Blueprint Medicines Could Be ‘Attractive Target For Partnerships’: Analyst Sanofi will pay $129.00 per share in cash, representing an equity value of ...

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib ...